drugset / Trial / NCT00144131
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare the efficacy (non-inferiority) of darbepoetin alfa (Aranesp®) extended dose schedule administration (EDS) versus darbepoetin alfa administered once per week (QW) in the treatment of anemia in subjects with non-myeloid malignancies receiving multi-cycle chemotherapy.
Timeline
- Start
- 2005-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 150 ug | — |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 300 ug | — |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 500 ug | — |